Frequently Asked Questions about Lyell Immunopharma, Inc. (LYEL)

Name: Lyell Immunopharma, Inc. (LYEL) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Lyell Immunopharma, Inc. (LYEL) do?

Accepted Answer

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo ...

Question 2

Is Lyell Immunopharma, Inc. (LYEL) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of LYEL reveals an Altman Z-Score of -4.59 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if LYEL fits their risk profile.

Question 3

What is the current P/E ratio for LYEL?

Accepted Answer

As of the latest trading session, Lyell Immunopharma, Inc. (LYEL) has a trailing P/E ratio of -1.36.

Question 4

Who is the CEO of Lyell Immunopharma, Inc.?

Accepted Answer

The current Chief Executive Officer of Lyell Immunopharma, Inc. is Lynn Seely.

Question 5

What was LYEL's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Lyell Immunopharma, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.08B (2022), $0.01B (2021) respectively.

Question 6

Does LYEL pay a dividend?

Accepted Answer

Lyell Immunopharma, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does LYEL have?

Accepted Answer

In its latest reporting period, Lyell Immunopharma, Inc. generated $-0.15B in Free Cash Flow against a total debt load of $0.04B.

Question 8

What is the Price-to-Book (P/B) ratio of Lyell Immunopharma, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Lyell Immunopharma, Inc. (LYEL) is currently 1.50.

Question 9

What is the Price-to-Sales (P/S) ratio of LYEL?

Accepted Answer

Based on trailing twelve-month data, Lyell Immunopharma, Inc. (LYEL) trades at a Price-to-Sales (P/S) ratio of 14100.80.

Question 10

What is Lyell Immunopharma, Inc.'s Return on Equity (ROE)?

Accepted Answer

Lyell Immunopharma, Inc. (LYEL) has a Return on Equity (ROE) of -90.52%, representing its profitability relative to shareholder equity.